Management of radiation-induced oral mucositis in head and neck cancer patients : a real-life survey among 25 Italian radiation oncology centers
© 2023. The Author(s)..
AIM: Radiation-induced oral mucositis (RIOM) is the most frequent side effect in head and neck cancer (HNC) patients treated with curative radiotherapy (RT). A standardized strategy for preventing and treating RIOM has not been defined. Aim of this study was to perform a real-life survey on RIOM management among Italian RT centers.
METHODS: A 40-question survey was administered to 25 radiation oncologists working in 25 different RT centers across Italy.
RESULTS: A total of 1554 HNC patients have been treated in the participating centers in 2021, the majority (median across the centers 91%) with curative intent. Median treatment time was 41 days, with a mean percentage of interruption due to toxicity of 14.5%. Eighty percent of responders provide written oral cavity hygiene recommendations. Regarding RIOM prevention, sodium bicarbonate mouthwashes, oral mucosa barrier agents, and hyaluronic acid-based mouthwashes were the most frequent topic agents used. Regarding RIOM treatment, 14 (56%) centers relied on literature evidence, while internal guidelines were available in 13 centers (44%). Grade (G)1 mucositis is mostly treated with sodium bicarbonate mouthwashes, oral mucosa barrier agents, and steroids, while hyaluronic acid-based agents, local anesthetics, and benzydamine were the most used in mucositis G2/G3. Steroids, painkillers, and anti-inflammatory drugs were the most frequent systemic agents used independently from the RIOM severity.
CONCLUSION: Great variety of strategies exist among Italian centers in RIOM management for HNC patients. Whether different strategies could impact patients' compliance and overall treatment time of the radiation course is still unclear and needs further investigation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 32(2023), 1 vom: 19. Dez., Seite 38 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
8MDF5V39QO |
|---|
| Anmerkungen: |
Date Completed 20.12.2023 Date Revised 15.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00520-023-08185-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366012673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366012673 | ||
| 003 | DE-627 | ||
| 005 | 20240116231951.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-023-08185-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1261.xml |
| 035 | |a (DE-627)NLM366012673 | ||
| 035 | |a (NLM)38110572 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bergamaschi, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of radiation-induced oral mucositis in head and neck cancer patients |b a real-life survey among 25 Italian radiation oncology centers |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2023 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a AIM: Radiation-induced oral mucositis (RIOM) is the most frequent side effect in head and neck cancer (HNC) patients treated with curative radiotherapy (RT). A standardized strategy for preventing and treating RIOM has not been defined. Aim of this study was to perform a real-life survey on RIOM management among Italian RT centers | ||
| 520 | |a METHODS: A 40-question survey was administered to 25 radiation oncologists working in 25 different RT centers across Italy | ||
| 520 | |a RESULTS: A total of 1554 HNC patients have been treated in the participating centers in 2021, the majority (median across the centers 91%) with curative intent. Median treatment time was 41 days, with a mean percentage of interruption due to toxicity of 14.5%. Eighty percent of responders provide written oral cavity hygiene recommendations. Regarding RIOM prevention, sodium bicarbonate mouthwashes, oral mucosa barrier agents, and hyaluronic acid-based mouthwashes were the most frequent topic agents used. Regarding RIOM treatment, 14 (56%) centers relied on literature evidence, while internal guidelines were available in 13 centers (44%). Grade (G)1 mucositis is mostly treated with sodium bicarbonate mouthwashes, oral mucosa barrier agents, and steroids, while hyaluronic acid-based agents, local anesthetics, and benzydamine were the most used in mucositis G2/G3. Steroids, painkillers, and anti-inflammatory drugs were the most frequent systemic agents used independently from the RIOM severity | ||
| 520 | |a CONCLUSION: Great variety of strategies exist among Italian centers in RIOM management for HNC patients. Whether different strategies could impact patients' compliance and overall treatment time of the radiation course is still unclear and needs further investigation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Radiation-induced oral mucositis | |
| 650 | 4 | |a Real-life survey | |
| 650 | 7 | |a Mouthwashes |2 NLM | |
| 650 | 7 | |a Sodium Bicarbonate |2 NLM | |
| 650 | 7 | |a 8MDF5V39QO |2 NLM | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Vincini, Maria Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Zaffaroni, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Pepa, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Angelicone, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Astone, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bergamini, Cristiana |e verfasserin |4 aut | |
| 700 | 1 | |a Buonopane, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a De Rosa, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Deantoni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Dell'Oca, Italo |e verfasserin |4 aut | |
| 700 | 1 | |a Di Gennaro, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Di Muzio, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Osti, Mattia Falchetto |e verfasserin |4 aut | |
| 700 | 1 | |a Federico, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Ferini, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Franzese, Ciro |e verfasserin |4 aut | |
| 700 | 1 | |a Gatti, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Grillo, Antonietta |e verfasserin |4 aut | |
| 700 | 1 | |a Iorio, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Manzo, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Marmiroli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzuca, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Molinaro, Maria Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Pacelli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Pepe, Alfonsina |e verfasserin |4 aut | |
| 700 | 1 | |a Perillo, Annarita |e verfasserin |4 aut | |
| 700 | 1 | |a Russo, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Salerno, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Spadaro, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Iorio, Giuseppe Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Muto, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Ricardi, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Alterio, Daniela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |d 1994 |g 32(2023), 1 vom: 19. Dez., Seite 38 |w (DE-627)NLM07487618X |x 1433-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:1 |g day:19 |g month:12 |g pages:38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00520-023-08185-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 1 |b 19 |c 12 |h 38 | ||